Mabwell's 9MW5211 Receives NMPA and FDA Clearance for Inflammatory Bowel Disease Clinical Trials
Key Insights
Mabwell (search)'s 9MW5211 (search) injection received NMPA clinical trial approval for inflammatory bowel disease (search) (IBD), with parallel FDA clearance in the United States.
The company is also advancing clinical trial applications for multiple sclerosis (search) and other indications, signaling a broad autoimmune disease pipeline strategy.
Separately, Mabwell (search)'s 6MW5311 (search) for injection obtained FDA approval to proceed with trials in hematologic malignancies including AML, CMML, and multiple myeloma (search).
Mabwell (search) (02493.HK) has achieved dual regulatory milestones for its investigational therapy 9MW5211 (search), with the National Medical Products Administration (NMPA) approving the clinical trial application for inflammatory bowel disease (search) (IBD) and the U.S. Food and Drug Administration (FDA) clearing the same indication for clinical investigation in the United States.
The company announced receipt of the "Notice of Approval for Drug Clinical Trial" from the NMPA, formally greenlighting the 9MW5211 (search) injection for clinical evaluation in IBD. Simultaneously, the FDA has cleared the U.S. clinical trial application for the IBD indication, positioning the program for transcontinental development.
Beyond IBD, Mabwell (search) disclosed that clinical trial applications for multiple sclerosis (search) (MS) and other indications have been accepted by the NMPA, with the company actively advancing additional submissions. The breadth of indications under investigation suggests a strategic focus on immune-mediated conditions.
Parallel Progress in Hematologic Malignancies
In a separate regulatory development, Mabwell (search) reported that its 6MW5311 (search) for injection has received a "Study May Proceed" letter from the FDA, formally approving the clinical trial application for hematologic malignancies. The approved indications include acute myeloid leukemia (search) (AML), chronic myelomonocytic leukemia (search) (CMML), and multiple myeloma (search) (MM). The clinical trial application for 6MW5311 has also been accepted by the NMPA, indicating parallel regulatory advancement in both the U.S. and China.
The dual-track regulatory progress across both autoimmune and oncology programs underscores Mabwell (search)'s expanding clinical pipeline and its commitment to pursuing global clinical development pathways for its biologic candidates.